Opdivo® (nivolumab) – New indication
August 17, 2018 - Bristol-Myers Squibb announced the FDA approval of Opdivo (nivolumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.
Download PDF
